Genetically Engineered Cell Production from Single Apheresis Sample
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for obtaining hematopoietic stem cells for clinical use often require multiple apheresis procedures and do not efficiently utilize the entire apheresis sample, which includes both hematopoietic stem cells and peripheral blood mononuclear cells, limiting the resource efficiency and therapeutic potential of genetically engineered cells for hyperproliferative diseases.
Innovation Solution
Genetically engineered lymphocytes and hematopoietic stem cells are produced from a single apheresis sample obtained after hematopoietic stem cell mobilization, using apheresis samples that contain both CD34+ cells and peripheral blood mononuclear cells, allowing for the generation of CAR-expressing cells that target lineage-specific cell-surface antigens associated with hyperproliferative diseases, such as hematopoietic malignancies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If multiple apheresis procedures are performed to obtain sufficient hematopoietic stem cells and lymphocytes, then the quantity of cells for therapy is improved, but the loss of time and increased procedural complexity worsen
Solution Approach 1:
The patent combines the collection of hematopoietic stem cells and lymphocytes into a single apheresis procedure. The method processes the entire apheresis sample to separate CD34+ cells for hematopoietic stem cell therapy and PBMCs containing lymphocytes for CAR-T cell therapy, thereby obtaining sufficient quantities of both cell types from one procedure rather than requiring multiple separate apheresis procedures.
Solution Approach 2:
The apheresis sample serves multiple functions simultaneously: it provides both hematopoietic stem cells (CD34+ cells) and lymphocytes (in PBMCs) for different therapeutic applications. The single sample is processed to generate two distinct therapeutic cell products, maximizing the utility of the collected blood cells and eliminating the need for separate collection procedures for each cell type.
2Loss of energy
If the entire apheresis sample is utilized to produce both hematopoietic stem cells and lymphocytes, then resource efficiency is improved, but the device complexity and processing requirements worsen
Solution Approach 1:
The patent segments the apheresis sample processing into distinct steps: first separating CD34+ hematopoietic stem cells from the sample, then isolating peripheral blood mononuclear cells (PBMCs) containing lymphocytes from the remaining sample. This segmentation allows systematic processing of different cell populations using standard apheresis and cell separation technologies, making the complex task manageable through structured sequential operations.
Solution Approach 2:
The patent uses peripheral blood mononuclear cells (PBMCs) as an intermediary fraction in the processing workflow. After CD34+ cells are removed from the apheresis sample, the PBMC layer is isolated as an intermediate product that contains the lymphocytes needed for CAR-T cell therapy. This intermediary step facilitates the efficient extraction of both cell types without requiring direct complex separation between all cell populations simultaneously.
3Manufacturing precision
If only a subset of the apheresis sample is harvested for hematopoietic stem cells, then the manufacturing precision for stem cell purity is improved, but the loss of substance and therapeutic potential worsen
Solution Approach 1:
The patent recovers previously discarded or underutilized components of the apheresis sample. After hematopoietic stem cells (CD34+ cells) are harvested with high purity, the remaining sample containing peripheral blood mononuclear cells (PBMCs) is not discarded but instead is processed to isolate lymphocytes for CAR-T cell therapy. This recovery approach ensures that valuable therapeutic cells are not wasted and maximizes the therapeutic potential of the original blood sample.
Data Source
AI summary
The disclosure is directed to methods and compositions relating to genetically engineered cells expressing chimeric antigen receptors, where the cells are mobilized lymphocytes.